Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 3/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 3/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2642501 | 0.81 | TSHR (0.50) | COMTCXCR2ALDH1A1L3MBTL1CTSS | |
| SCHEMBL28039072 | 0.81 | ALDH1A1 (0.51) | COMTALDH1A1L3MBTL1CTSSTSHR | |
| SCHEMBL2642487 | 0.80 | ALDH1A1 (0.40) | COMTCXCR2ALDH1A1L3MBTL1CTSS | |
| SCHEMBL9540649 | 0.77 | ACLY (0.43) | ALDH1A1L3MBTL1ACLYTSHRMAPT | |
| SCHEMBL10423502 | 0.75 | TTR (0.42) | ALDH1A1ACLYTSHRMAPTMAPK1 | |
| SCHEMBL27812266 | 0.75 | ACLY (0.42) | ALDH1A1ACLYTSHRMAPTMAPK1 | |
| SCHEMBL6657862 | 0.73 | CA1 (0.55) | ALDH1A1ACLYTSHR | |
| SCHEMBL2642805 | 0.73 | HSD11B1 (0.42) | ALDH1A1ACLYTSHR | |
| Hydrochloric Acid SCHEMBL27286541 | 0.73 | ACLY (0.41) | ALDH1A1ACLYTSHRMAPTMAPK1 | |
| SCHEMBL2642878 | 0.70 | CXCR2 (0.43) | COMTCXCR2ALDH1A1ACLYTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687502-B2 | Substituted quinazoline or pyridopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | MSD K.K. (JP) | 2008-02-07 | — | — | US | disclosed |
| EP-1734040-A1 | SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | GCK, GCKR, PDXK | COMT 2306/4885CXCR2 1500/4885ALDH1A1 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.